RANI THERAP.H. A DL-,0001 Aktie

Rani Therapeutics showcased its RaniPill platform at the Canaccord Growth Conference, saying it can deliver 80–85% of typical market biologics orally with subcutaneous-like bioavailability. The company highlighted a $1 billion partnership with Chugai as validation and reported that RT-114 achieved a relative bioavailability of over 150% versus subcutaneous dosing in Phase I-a. Rani has $43 million in cash and marketable securities, expected to last through Q4 2027, and is pursuing partnerships rather than building its own salesforce; production lines for various indications are being ramped up. Management cites scaling costs, partner dependence and strong competition in the obesity market as the main risks. » Plus sur de.investing.com

Rani Therapeutics reports positive results from a Phase‑1a single‑dose study of RT-114, a RaniPill‑delivered capsule containing the GLP‑1/GLP‑2 dual agonist PG‑102. In 30 healthy volunteers, oral dosing produced more than 150% higher systemic exposure than subcutaneous injection; there were no serious adverse events and no capsule‑related adverse events. Half‑life was 5.6 days versus 5.3 days. The company is expanding the study by 15 additional subjects with repeated dosing to identify a dose for a planned Phase‑1b in obese patients, with the trial expected to start in 2026 and first data anticipated in 2027. Development is happening in partnership with ProGen, with costs and revenues split 50:50; the stock has fallen sharply year to date. » Plus sur de.investing.com

Rani Therapeutics and PegBio have launched an R&D collaboration to explore oral delivery of obesity and metabolic therapeutics using the RaniPill platform. The partners plan to develop preclinical RaniPill formulations for multiple PegBio molecules with the aim of advancing those candidates into clinical development. The agreement expands Rani’s obesity programs alongside the existing RT-114 project; financial terms and specific molecules were not disclosed. » Plus sur de.investing.com